Consistent data matters. Prolaris® is the best answer for your prostate cancer patients. Submit the form below to learn why.
Prolaris: Your NEW ADT decision tool
When it comes to treating NCCN intermediate- and high-risk prostate cancer, it can be challenging to know which patients could truly benefit from the use of ADT (Androgen Deprivation Therapy) + RT (Radiation Therapy). The Prolaris white paper tells our exclusive story of consistent data across our validation and utility studies; giving you confidence to choose Prolaris when you need to know which patients would have little to no benefit from ADT.
Request Prolaris White Paper